STOCK TITAN
  1. Home
  2. Sec-filings
  3. ATXS
  4. [EFFECT] Astria Therapeutics, Inc. SEC Filing

[EFFECT] Astria Therapeutics, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: January 27, 2026
Accession Number: 0001140361-26-002205
Submission Type: POS AM
CIK: 0001454789
Company Name: Astria Therapeutics, Inc.
File Number: 333-254174

Source: View Original Filing on SEC EDGAR

Stock ATXS logo
Astria Therapeutics Inc

NASDAQ:ATXS

ATXS Rankings

#3124 Ranked by Market Cap
N/A Ranked by Dividends

ATXS Latest News

Jan 21, 2026
Astria Stockholders Vote to Approve Acquisition by BioCryst
Nov 12, 2025
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Nov 10, 2025
Intel Appoints Dr. Craig H. Barratt to Board of Directors
Nov 6, 2025
Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart
Oct 31, 2025
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

ATXS Latest SEC Filings

Feb 2, 2026
[15-12G] Astria Therapeutics, Inc. SEC Filing
Jan 28, 2026
[SCHEDULE 13D/A] Astria Therapeutics, Inc. Amended Major Shareholder Report
Jan 28, 2026
[EFFECT] Astria Therapeutics, Inc. SEC Filing
Jan 28, 2026
[EFFECT] Astria Therapeutics, Inc. SEC Filing
Jan 28, 2026
[EFFECT] Astria Therapeutics, Inc. SEC Filing

ATXS Stock Data

718.13M
50.32M
0.49%
102.52%
4.94%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON